Herti 440mg Injection

Herti 440 mg Injection is a monoclonal antibody that specifically targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in certain types of cancer cells, particularly HER2-positive breast and gastric cancers.

HER2 is a receptor on the surface of cells that promotes cell growth and division. In cancers where HER2 is overexpressed, the cells grow and divide uncontrollably. Trastuzumab binds to the extracellular domain of the HER2 receptor, blocking its activation. This prevents downstream signaling that promotes cancer cell growth and survival.

Herti 440 mg Injection works by targeting and binding to the HER2 receptor, which helps slow down the growth and replication of cancer cells. While it is effective, it may cause some common side effects such as fever, cough, headache, rash, infections, and sleep disturbances. More serious side effects can include heart failure, allergic reactions, and lung problems. Its use during pregnancy may pose risks to the unborn baby.

Herti 440 mg Injection is given as an IV infusion by a healthcare professional. It may be given weekly or every three weeks, depending on the treatment plan. Pre-medication might be used to reduce infusion reactions. The powder is reconstituted and diluted before use under sterile conditions. Heart function and vital signs are monitored during treatment. Herti should never be self-administered.

Herti 440 mg Injection is used in the treatment of HER2-positive cancers, specifically:

Herti 440 mg Injection is used to treat both early-stage and metastatic HER2-positive breast cancer. It may be given alone or in combination with chemotherapy.

It is also used in combination with other cancer medicines to treat advanced HER2-positive gastric or gastroesophageal junction cancer.

Herti 440 mg Injection works by targeting the HER2 receptors on cancer cells, slowing their growth and helping the immune system destroy them. It is only used in patients whose cancer cells test positive for the HER2 protein.

Herti 440 mg Injection is a biosimilar of trastuzumab that works by targeting a protein called HER2 (Human Epidermal Growth Factor Receptor 2). This protein is present in large amounts on the surface of certain cancer cells. Herti is a monoclonal antibody, meaning it is specially designed to attach itself to the HER2 receptor and block its harmful effects.

Once it binds to HER2, Herti helps stop the cancer cells from growing and surviving. It blocks the signals that encourage cancer growth, directs the immune system to attack and destroy HER2-positive cancer cells, and also reduces the activity of HER2 on the cell surface. Together, these actions slow down tumor growth, lower cancer cell survival, and boost the body’s immune response against the cancer.

Side Effects of Herti 440 mg Injection

Like all medications, Herti 440 mg Injection may cause side effects. However, not everyone will experience them.

Serious Side Effects (Seek immediate medical attention):

• Heart problems (e.g., heart failure, irregular heartbeat, shortness of breath)
• Severe allergic reactions (swelling of face/lips, difficulty breathing, itching, or rash)
• Lung toxicity (trouble breathing, fluid in lungs, cough with fever)
• Infusion related reactions (severe drop in blood pressure, chest pain, difficulty breathing)
• Liver function abnormalities (elevated liver enzymes)
• Low white blood cell count (increased risk of infections)

Common Side Effects (Usually mild and temporary):

• • Fever or chills
  • Nausea or vomiting
  • Headache
  • Cough
  • Diarrhea
  • Weakness or fatigue
  • Rash
  • Body pain or joint pain
  • Trouble sleeping
  • Injection site reactions (pain, redness, or swelling)

Herti 440 mg (Trastuzumab) is given as an intravenous (IV) infusion by a qualified healthcare professional experienced in cancer care. The treatment starts with a loading dose of 8 mg/kg, which is infused slowly over about 90 minutes. During and after this infusion, patients are carefully monitored for any possible reactions.

After the loading dose, patients receive a maintenance dose of 6 mg/kg once every 3 weeks (21-day cycle). This dose is usually given over 30 to 90 minutes, depending on how well the patient tolerates the infusion.

The dosage is calculated based on the patient’s actual body weight. Herti should never be given as a rapid or bolus injection. If serious infusion reactions or heart-related problems occur, the doctor may adjust the dose. It is important to always follow the oncologist’s instructions and the hospital’s treatment guidelines.